Compare ASTRAZENECA PHARMA with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs BIOCON - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA BIOCON ASTRAZENECA PHARMA/
BIOCON
 
P/E (TTM) x 96.6 22.2 434.4% View Chart
P/BV x 27.2 2.9 923.7% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   BIOCON
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
BIOCON
Mar-18
ASTRAZENECA PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,2781,188 107.6%   
Low Rs883305 289.4%   
Sales per share (Unadj.) Rs228.468.7 332.3%  
Earnings per share (Unadj.) Rs10.47.6 137.2%  
Cash flow per share (Unadj.) Rs16.314.0 116.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs98.886.3 114.4%  
Shares outstanding (eoy) m25.00600.00 4.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.710.9 43.5%   
Avg P/E ratio x104.298.9 105.4%  
P/CF ratio (eoy) x66.453.4 124.3%  
Price / Book Value ratio x10.98.6 126.5%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m27,008447,900 6.0%   
No. of employees `0001.46.1 22.1%   
Total wages/salary Rs m1,5359,311 16.5%   
Avg. sales/employee Rs Th4,210.96,705.8 62.8%   
Avg. wages/employee Rs Th1,132.21,514.2 74.8%   
Avg. net profit/employee Rs Th191.1736.9 25.9%   
INCOME DATA
Net Sales Rs m5,71041,234 13.8%  
Other income Rs m1232,062 5.9%   
Total revenues Rs m5,83343,296 13.5%   
Gross profit Rs m4638,291 5.6%  
Depreciation Rs m1473,851 3.8%   
Interest Rs m0615 0.0%   
Profit before tax Rs m4385,887 7.4%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,569 11.4%   
Profit after tax Rs m2594,531 5.7%  
Gross profit margin %8.120.1 40.3%  
Effective tax rate %40.826.7 153.3%   
Net profit margin %4.511.0 41.3%  
BALANCE SHEET DATA
Current assets Rs m3,20941,486 7.7%   
Current liabilities Rs m2,07021,413 9.7%   
Net working cap to sales %20.048.7 41.0%  
Current ratio x1.61.9 80.0%  
Inventory Days Days7264 113.1%  
Debtors Days Days3594 37.1%  
Net fixed assets Rs m79050,661 1.6%   
Share capital Rs m503,000 1.7%   
"Free" reserves Rs m2,41948,808 5.0%   
Net worth Rs m2,46951,808 4.8%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m4,60599,897 4.6%  
Interest coverage xNM10.6-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.4 300.4%   
Return on assets %5.65.2 109.2%  
Return on equity %10.58.7 120.0%  
Return on capital %17.79.6 184.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30012,058 2.5%   
Fx outflow Rs m2,0157,348 27.4%   
Net fx Rs m-1,7154,710 -36.4%   
CASH FLOW
From Operations Rs m886,621 1.3%  
From Investments Rs m-94-6,840 1.4%  
From Financial Activity Rs mNA-2,397 0.0%  
Net Cashflow Rs m-6-2,612 0.2%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 0.3 8.4 3.6%  
FIIs % 15.7 10.7 146.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.9 45.7%  
Shareholders   12,856 109,995 11.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 76 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile day marginally lower.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 21, 2019 03:37 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS